ESPER BIOSCIENCES INC
ITHACA, NY · Medtech · Private
Point-of-care nanosensor-based nucleic acid diagnostic device for Hepatitis C genotyping and viral load quantification
- Grants
- $1.9M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- $300K
- 1 award · Health and Human S
- #421 of 4531 in medtech
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Nanopore-integrated carbon nanotube sensors for DNA sequencing | $150,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Nanopore-integrated carbon nanotube sensors for DNA sequencing | $150,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Epigenetic fingerprinting of label-free DNA using a solid-state nanopore | $279,974 | |
| Federal grant | Department of Health and Human Services · Phase I · Epigenetic fingerprinting of label free DNA using a solid state nanopore | $279,974 | |
| Federal grant | Department of Health and Human Services · Phase I · DNA labeling for improved synthetic long reads | $329,887 | |
| Federal contract | Department of Health and Human Services · Hepatitis C Diagnostics Using Nanopore Field-effect Sensors | $299,889 | |
| Federal grant | Department of Health and Human Services · Phase I · Rapid Point-of-Care Nucleic Acid Test for Hepatitis C using Nanosensors | $423,833 |
Federal grant · SBIR/STTRFederal contract · USAspending
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 418 | CORGENIX MEDICAL CORPORATION | $301K | — |
| 419 | TheraNano LLC | $300K | — |
| 420 | LIFETIME OMICS, INC. | $300K | — |
| 421 | ESPER BIOSCIENCES INC | $300K | — |
| 422 | DARWIN BIOSCIENCES, INC. | $299K | — |
| 423 | SEVIDENT, INC. | $299K | — |
| 424 | SALUS DISCOVERY LLC | $299K | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.